Stocktoria
UCB SA UCB.BR
BE · Euronext Brussels · XBRU · stock · Healthcare · website
UCB SA financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €7.7B | €6.2B | €5.3B | €5.5B |
| Gross profit | €5.8B | €4.4B | €3.5B | €3.8B |
| R&D expense | €1.8B | €1.8B | €1.6B | €1.7B |
| SG&A expense | €2.7B | €2.3B | €1.8B | €1.7B |
| Operating income | €2.0B | €846.0M | €633.0M | €701.0M |
| Interest expense | €128.0M | €159.0M | €144.0M | €71.0M |
| Income tax | €264.0M | €98.0M | €98.0M | €91.0M |
| Net income | €1.6B | €1.1B | €343.0M | €418.0M |
| EPS (diluted) | €8.03 | — | €1.76 | €2.14 |
| Operating cash flow | €2.3B | €1.2B | €761.0M | €1.1B |
| Free cash flow | €1.8B | €920.0M | €445.0M | €748.0M |
| Cash & equivalents | €2.3B | €1.6B | €861.0M | €899.0M |
| Inventory | €1.5B | €1.3B | €1.0B | €907.0M |
| Total assets | €18.2B | €17.3B | €15.5B | €15.9B |
| Total liabilities | €7.3B | €7.3B | €6.6B | €6.8B |
| Shareholders' equity | €10.9B | €10.0B | €9.0B | €9.1B |
Growth · year-over-year · Revenue CAGR 12%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +25.8% | +17.1% | -4.8% | — |
| Net income growth | +46.3% | +210.5% | -17.9% | — |
| EPS growth | — | — | -17.8% | — |
| Free cash flow growth | +100.2% | +106.7% | -40.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · BE · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.